Aubrey  Rankin net worth and biography

Aubrey Rankin Biography and Net Worth

Aubrey Rankin joined Revance Therapeutics in 2020 as President of Innovation & Technology. 

Previously, Mr. Rankin was the co-founder & CEO of HintMD, a fintech platform developed specific for medical aesthetic practices; which was acquired by Revance Therapeutics in 2020.   

Prior to co-founding HintMD, Mr. Rankin served as Vice President of Asia-Pacific at ZELTIQ Aesthetics (ZLTQ). During his tenure, he led accelerated growth in the Asia-Pacific region and was part of a larger management team responsible for one of the most successful business turn-around efforts within the medical aesthetics industry. 

Mr. Rankin was formerly a Director within PwC’ Mergers and Acquisitions Advisory group, during which he assisted multinational clients on M&A, Divestitures and Strategic Alliance projects ranging from $50M to $3.6B in value. His clients included key Fortune 500, Private Equity, and Silicon Valley start-up companies within software, entertainment, retail and life sciences industries. 

Mr. Rankin currently serves as strategic advisor to the board of directors of Sciton, PB&B, and FriendMedia. He holds an MBA from Strayer University and a B.Sc. degree from the University of Stellenbosch.

What is Aubrey Rankin's net worth?

The estimated net worth of Aubrey Rankin is at least $223,372.80 as of July 28th, 2021. Mr. Rankin owns 79,776 shares of Revance Therapeutics stock worth more than $223,373 as of June 19th. This net worth evaluation does not reflect any other investments that Mr. Rankin may own. Learn More about Aubrey Rankin's net worth.

How do I contact Aubrey Rankin?

The corporate mailing address for Mr. Rankin and other Revance Therapeutics executives is 7555 GATEWAY BLVD., NEWARK CA, 94560. Revance Therapeutics can also be reached via phone at (615) 724-7755 and via email at [email protected]. Learn More on Aubrey Rankin's contact information.

Has Aubrey Rankin been buying or selling shares of Revance Therapeutics?

Aubrey Rankin has not been actively trading shares of Revance Therapeutics over the course of the past ninety days. Most recently, on Friday, December 3rd, Aubrey Rankin bought 30,000 shares of Revance Therapeutics stock. The stock was acquired at an average cost of $14.43 per share, with a total value of $432,900.00. Learn More on Aubrey Rankin's trading history.

Who are Revance Therapeutics' active insiders?

Revance Therapeutics' insider roster includes Mark Foley (CEO), Dwight Moxie (SVP), Aubrey Rankin (Insider), Angus Russell (Director), and Tobin Schilke (CFO & Principal Accounting Officer ). Learn More on Revance Therapeutics' active insiders.

Are insiders buying or selling shares of Revance Therapeutics?

In the last twelve months, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 107,201 shares worth more than $1,859,572.74. The most recent insider tranaction occured on April, 16th when insider Erica Jordan sold 2,392 shares worth more than $9,089.60. Insiders at Revance Therapeutics own 3.5% of the company. Learn More about insider trades at Revance Therapeutics.

Information on this page was last updated on 4/16/2024.

Aubrey Rankin Insider Trading History at Revance Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2021Buy30,000$14.43$432,900.00View SEC Filing Icon  
8/16/2021Sell9,364$26.34$246,647.76View SEC Filing Icon  
7/28/2021Sell54,332$30.06$1,633,219.9279,776View SEC Filing Icon  
7/26/2021Sell55,382$29.72$1,645,953.0479,776View SEC Filing Icon  
4/5/2021Sell2$28.28$56.5679,776View SEC Filing Icon  
3/4/2021Sell33,119$25.43$842,216.1779,776View SEC Filing Icon  
2/1/2021Sell33,119$25.95$859,438.0567,871View SEC Filing Icon  
11/30/2020Sell33,119$23.85$789,888.1567,871View SEC Filing Icon  
10/29/2020Sell33,119$26.15$866,061.8567,871View SEC Filing Icon  
9/28/2020Sell33,119$26.18$867,055.4267,871View SEC Filing Icon  
See Full Table

Aubrey Rankin Buying and Selling Activity at Revance Therapeutics

This chart shows Aubrey Rankin's buying and selling at Revance Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Revance Therapeutics Company Overview

Revance Therapeutics logo
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Read More

Today's Range

Now: $2.80
Low: $2.74
High: $2.90

50 Day Range

MA: $3.36
Low: $2.67
High: $4.44

2 Week Range

Now: $2.80
Low: $2.57
High: $29.43


1,428,356 shs

Average Volume

1,605,170 shs

Market Capitalization

$292.46 million

P/E Ratio


Dividend Yield